IP Verse

Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist - EP3470432B1

PatentPatent Analysis

EP3470432

REGENERON PHARMACEUTICALS
Application Number
EP18194745A
Filing Date
Aug 20, 2013
Status
Revoked
May 19, 2023
Grant Date
Oct 6, 2021
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP4252857B1
EP3506931B1
EP3889181B1

Bibliography

The patent EP3470432B1 was granted to Regeneron Pharmaceuticals on Oct 6, 2021 following the initial filing on Aug 20, 2013 under the application number EP18194745A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

D YOUNGJul 6, 2022ADMISSIBLE
NEUEFEINDJul 6, 2022ADMISSIBLE
DR H ULRICH DORRIESJul 5, 2022ADMISSIBLE
SECERNAJul 5, 2022ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents